Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Amortization - Intangibles (2019 - 2024)

Akebia Therapeutics has reported Amortization - Intangibles over the past 6 years, most recently at $9.0 million for Q4 2024.

  • Quarterly Amortization - Intangibles changed 0.0% to $9.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Sep 2025, down 75.0% year-over-year, with the annual reading at $36.0 million for FY2024, 0.0% changed from the prior year.
  • Amortization - Intangibles was $9.0 million for Q4 2024 at Akebia Therapeutics, roughly flat from $9.0 million in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $9.1 million in Q2 2020 and troughed at $6.1 million in Q3 2020.
  • The 5-year median for Amortization - Intangibles is $9.0 million (2021), against an average of $8.8 million.
  • Year-over-year, Amortization - Intangibles plummeted 32.91% in 2020 and then skyrocketed 47.58% in 2021.
  • A 5-year view of Amortization - Intangibles shows it stood at $8.3 million in 2020, then grew by 8.42% to $9.0 million in 2021, then changed by 0.0% to $9.0 million in 2022, then changed by 0.0% to $9.0 million in 2023, then changed by 0.0% to $9.0 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Amortization - Intangibles are $9.0 million (Q4 2024), $9.0 million (Q3 2024), and $9.0 million (Q2 2024).